Voya Investment Management LLC Boosts Stock Position in Medpace Holdings, Inc. $MEDP

Voya Investment Management LLC raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,976 shares of the company’s stock after purchasing an additional 1,560 shares during the period. Voya Investment Management LLC owned 0.08% of Medpace worth $6,696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Whittier Trust Co. increased its stake in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after buying an additional 35 shares during the period. Benjamin Edwards Inc. lifted its position in shares of Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company’s stock valued at $366,000 after buying an additional 36 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after purchasing an additional 43 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its position in shares of Medpace by 6.4% in the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company’s stock worth $237,000 after purchasing an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Kevin M. Brady sold 12,000 shares of the business’s stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at approximately $2,725,380. The trade was a 66.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares in the company, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by insiders.

Medpace Stock Performance

Shares of Medpace stock opened at $497.83 on Thursday. The firm has a 50-day simple moving average of $439.91 and a two-hundred day simple moving average of $352.60. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $506.55. The company has a market cap of $13.98 billion, a P/E ratio of 37.01, a price-to-earnings-growth ratio of 3.09 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MEDP. William Blair reaffirmed a “market perform” rating on shares of Medpace in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a report on Wednesday, July 23rd. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Barclays upped their price target on shares of Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd. Finally, Cowen cut shares of Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Reduce” and an average price target of $422.27.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.